The American Journal of Managed Care
FDA Reverses Course, Will Review Moderna’s mRNA Flu Vaccine
The FDA will now review Moderna’s seasonal mRNA influenza vaccine application, setting a mid-2026 decision date. In a regulatory turnaround, the FDA will now review Moderna’s seasonal mRNA flu vaccine ...
The Baltimore Sun
FDA agrees to review Moderna mRNA flu vaccine after initial refusal-to-file
The Food and Drug Administration reversed course on Wednesday and agreed to formally review Moderna’s new flu vaccine that uses mRNA technology, the company announced in a news release. Earlier this ...
Yahoo
FDA reverses course, will review Moderna’s mRNA flu vaccine candidate
Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration (FDA) has backtracked its initial decision last week of refusing to review Moderna’s mRNA flu ...
Yahoo
FDA reverses course and will review Moderna’s mRNA-based flu shot
Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration has reversed course and agreed to review Moderna’s application for the first mRNA-based flu ...
WLWT
FDA reverses course and will review Moderna’s mRNA flu shot, company says
The U.S. Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the pharmaceutical company said Wednesday.About two weeks ago, the FDA sent Moderna a ...
Detroit News
FDA reverses course and will review Moderna’s mRNA-based flu shot
The Food and Drug Administration has reversed course and agreed to review Moderna’s application for the first mRNA-based flu vaccine under a revised approach, company and federal officials said ...